Patient Derived Xenograft (PDX) Models Market Report 2026

The patient derived xenograft (pdx) models market size has grown rapidly in recent years. It will grow from $0.47 billion in 2025 to $0.54 billion in 2026 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to limited predictive capability of traditional cell line models, increasing cancer research initiatives, reliance on animal models for drug testing, growing demand for translational oncology studies, expansion of academic and pharmaceutical research collaborations.

The patient derived xenograft (pdx) models market size is expected to see rapid growth in the next few years. It will grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to rising adoption of pdx models for precision medicine, increasing investment in humanized mouse and rat models, growth of co-clinical trial programs, expansion of contract research services offering pdx solutions, increasing use of pdx models for immunotherapy and targeted therapy evaluation. Major trends in the forecast period include increasing adoption of pdx models for preclinical drug development, rising focus on personalized cancer research using pdx models, growing integration of digital platforms for tumor data management, increasing utilization of humanized and genetically modified models, rising expansion of co-clinical trials leveraging pdx models.

The growing demand for personalized medicine is expected to drive the expansion of the patient-derived xenograft (PDX) models market in the coming years. Personalized medicine involves customizing medical treatments for individual patients based on factors such as genetics, environment, and lifestyle. This demand is rising due to advancements in genomic research, which allow treatments to be tailored to a patient’s unique genetic profile, resulting in more precise and effective healthcare outcomes. Patient-derived xenograft (PDX) models support personalized medicine by enabling the testing of individual patient tumors to predict treatment responses and guide therapy decisions. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six approvals in 2022. Thus, the increasing focus on personalized medicine is fueling growth in the PDX models market.

Key companies in the patient-derived xenograft (PDX) models market are developing advanced models with in vivo bioluminescence imaging capabilities, allowing real-time monitoring of tumor growth. In vivo bioluminescence imaging enhances PDX models by providing noninvasive, real-time tracking of tumor metastasis and treatment responses, improving the efficiency of preclinical drug development research. For instance, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), launched an orthotopic model of human glioblastoma in NSG-SGM3 mice using patient-derived xenografts (PDX) combined with in vivo bioluminescence imaging. This model is designed to facilitate personalized treatment for glioblastoma, the most common and aggressive brain cancer, and is essential for understanding tumor biology and evaluating new targeted therapies and immunotherapies to enhance patient outcomes.

In October 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Modifi Biosciences, Inc., for $1.3 billion. This acquisition supports Merck’s strategy to expand its oncology portfolio by integrating Modifi’s innovative research, including preclinical drug candidates and PDX model data, to develop therapies targeting cancers with DNA repair deficiencies. Modifi Biosciences, Inc., is a US-based biotechnology company focused on cancer therapeutics through direct DNA modification.

Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin‑Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.

North America was the largest region in the patient derived xenograft (PDX) models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (pdx) models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the patient derived xenograft (pdx) models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the patient-derived xenograft (PDX) models market by increasing costs of importing specialized immunodeficient mice, rat models, and laboratory equipment. Academic institutions, pharmaceutical companies, and contract research organizations in north america, europe, and asia-pacific are most affected due to dependence on international suppliers. Higher costs may slow procurement of PDX models and delay preclinical research. However, tariffs also incentivize local breeding programs, regional model providers, and domestic laboratory infrastructure development, which supports long-term sustainability and supply chain resilience.

The patient derived xenograft (pdx) models market research report is one of a series of new reports that provides patient derived xenograft (pdx) models market statistics, including patient derived xenograft (pdx) models industry global market size, regional shares, competitors with a patient derived xenograft (pdx) models market share, detailed patient derived xenograft (pdx) models market segments, market trends and opportunities, and any further data you may need to thrive in the patient derived xenograft (pdx) models industry. This patient derived xenograft (pdx) models market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Patient-derived xenograft (PDX) models involve transplanting human tumor tissue into immunodeficient animal hosts. They replicate the complexity of human tumors more accurately than traditional cell line models. PDX models are essential for understanding tumor biology and evaluating potential cancer therapies before clinical trials.

The primary types in the patient-derived xenograft (PDX) models market are mice models and rat models. Mice models consist of laboratory mice that are genetically modified or specifically bred to study biological processes, diseases, or treatment responses, supporting biomedical and pharmaceutical research. Techniques include heterotopic and orthotopic implantation, and tumor types cover gastrointestinal, lung, hematological, gynecological, respiratory, urological, and other models. PDX models are used in preclinical drug development, precision medicine, co-clinical trials, and fundamental cancer research across academic institutions, research organizations, pharmaceutical companies, biotechnology firms, and others.

The patient derived xenograft (PDX) models market includes revenues earned by entities by providing services such as evaluating drug efficacy, studying tumor biology, and predicting patient-specific treatment responses in preclinical cancer research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.